# Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

> **NCT02145403** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 53 (actual)

## Conditions studied

- Hematologic Malignancies
- Relapse
- Graft-Versus-Host Disease

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT02145403
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-11-26
- **Final completion:** 2020-10-16
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2022-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02145403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02145403, "Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02145403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*